Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Nov 4;11(11):2657.
doi: 10.3390/nu11112657.

Enteral Nutrition in Patients with Inflammatory Bowel Disease. Systematic Review, Meta-Analysis, and Meta-Regression

Affiliations
Meta-Analysis

Enteral Nutrition in Patients with Inflammatory Bowel Disease. Systematic Review, Meta-Analysis, and Meta-Regression

Jose M Comeche et al. Nutrients. .

Abstract

Inflammatory bowel disease (IBD) is a chronic disease mediated by the immune system and is characterized by inflammation of the gastrointestinal tract. One of the possible treatments for this pathology is a change in the type of diet, of which enteral nutrition (EN) is one. This study is to understand how the use of EN can affect the adult population diagnosed with IBD. We conducted a systematic review, meta-analysis, and a meta-regression. On the different databases (MEDLINE, Scopus, Cochrane, LILACS, CINAHL, WOS), we found 363 registers with an accuracy of 12% (44 registers). After a full-text review, only 30 research studies were selected for qualitative synthesis and 11 for meta-analysis and meta-regression. The variables used were Crohn's disease activity index (CDAI), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). EN has been shown to have efficacy for the treatment of Crohn's disease and is compatible with other medicines. As for the CDAI or rates of remission, there were no differences between enteral and parenteral nutrition. Polymeric formulas have shown better results with respect to the CRP. The long-term treatment could dilute the good CDAI results that are obtained at the start of the EN treatment.

Keywords: Crohn’s disease; enteral nutrition; inflammatory bowel diseases; meta-analysis; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Identification and selection of the studies/records in the databases.
Figure 2
Figure 2
Chronological review according to the type of study and population.
Figure 3
Figure 3
Risk of bias summary across the clinical trials. Low risk of bias: green “+”; Some concerns of bias: yellow “?”, “!”; High risk of bias: red “−”.
Figure 4
Figure 4
Risk of bias graph across clinical trials. Low risk of bias: green; Some concerns of bias: yellow; High risk of bias: red.
Figure 5
Figure 5
Forest plot for the (a) Crohn’s disease activity index (CDAI), (b) C-reactive protein (CRP), (c) erythrocyte sedimentation rate (ESR). * Polymeric nutrition, # Elemental nutrition.
Figure 5
Figure 5
Forest plot for the (a) Crohn’s disease activity index (CDAI), (b) C-reactive protein (CRP), (c) erythrocyte sedimentation rate (ESR). * Polymeric nutrition, # Elemental nutrition.
Figure 6
Figure 6
Baujat plot for the (a) Crohn’s disease activity index (CDAI), (b) C-reactive protein (CRP), and (c) erythrocyte sedimentation rate (ESR). The correspondence between the study and the number is shown in Table 2 (ID, Omitting).
Figure 7
Figure 7
Funnel plot for the (a) Crohn’s disease activity index (CDAI), (b) C-reactive protein (CRP), and (c) erythrocyte sedimentation rate (ESR).

Similar articles

Cited by

References

    1. Celiberto L.S., Graef F.A., Healey G.R., Bosman E.S., Jacobson K., Sly L.M., Vallance B.A. Inflammatory bowel disease and immunonutrition: Novel therapeutic approaches through modulation of diet and the gut microbiome. Immunology. 2018;155:36–52. doi: 10.1111/imm.12939. - DOI - PMC - PubMed
    1. Cohen L.J., Cho J.H., Gevers D., Chu H. Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases. Gastroenterology. 2019;156:2174–2189. doi: 10.1053/j.gastro.2019.03.017. - DOI - PMC - PubMed
    1. Coward S., Clement F., Benchimol E.I., Bernstein C.N., Avina-Zubieta J.A., Bitton A., Carroll M.W., Hazlewood G., Jacobson K., Jelinski S., et al. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology. 2019;156:1345–1353. doi: 10.1053/j.gastro.2019.01.002. - DOI - PubMed
    1. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C.Y., Chan F.K.L., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed
    1. Reddavide R., Rotolo O., Caruso M.G., Stasi E., Notarnicola M., Miraglia C., Nouvenne A., Meschi T., De’ Angelis G.L., Di Mario F., et al. The role of diet in the prevention and treatment of inflammatory bowel diseases. Acta Biomed. 2018;89:60–75. - PMC - PubMed